RxDoctor Payments DataLook up a doctor →

Jeffrey Saver, MD

Neurology · Los Angeles, CANPI 1356369730

Payments from drug & device makers

$2,922,515in general payments, 2019–2025

Across 348 payments — averaging $8398.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rapid Medical Ltd$2.7M
  • E.r. Squibb & Sons, L.L.C.$46K
  • Medtronic$34K
  • Abbott$27K
  • CSL Behring$25K
  • Novo Nordisk$14K
  • plus $58K from 17 others
$56,736in research payments, 2019–2025

Across 21 payments — averaging $2701.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$29K
  • Novo Nordisk AS$21K
  • Stryker$4K
  • Rapid Medical Ltd$2K
  • Amgen$750

What the payments were for

  • Consulting fees$136,11964%
  • Speaking & faculty fees$53,03325%
  • Grants$1,1251%
  • Travel & lodging$19,6109%
  • Food & beverage$2,4491%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,922,515 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$29,723
Medicare patients
172
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab11$7,733
Praluent PenAlirocumab13$6,031
Cilostazol22$885
ClopidogrelClopidogrel Bisulfate17$414
Rosuvastatin Calcium12$141
Atorvastatin Calcium11$116

Paid to pharmacies, not to this prescriber.

Other neurology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →